Published in Kidney Int on August 01, 1994
Personalized Medicine for Membranous Nephropathy (PMMN) | NCT03804359
Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut (2002) 1.11
Confirmation of nosocomial transmission of hepatitis C virus by phylogenetic analysis of the NS5-B region. J Clin Microbiol (1998) 1.08
High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence. J Clin Microbiol (1996) 1.00
Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol (1998) 0.92
Transmission of hepatitis C virus in a gynecological surgery setting. J Clin Microbiol (2001) 0.89
The role of hemodialysis machines dedication in reducing Hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study. BMC Nephrol (2004) 0.84
Use of phylogenetic analysis of hepatitis C virus (HCV) hypervariable region 1 sequences to trace an outbreak of HCV in an autodialysis unit. J Clin Microbiol (2002) 0.82
Follow-up study of hepatitis C virus infection in uremic patients on maintenance hemodialysis for 30 months. World J Gastroenterol (2000) 0.80
Risk factors of hepatitis C virus infection in patients on hemodialysis: a multivariate analysis based on a dialysis register in Central Italy. Eur J Epidemiol (1999) 0.80
Reduced antibody reactivity to hepatitis C virus antigens in hemodialysis patients coinfected with hepatitis B virus. Clin Diagn Lab Immunol (1997) 0.79
Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. Eur J Clin Microbiol Infect Dis (2006) 0.78
Hepatitis C Virus Infection in Haemodialysis Patients: "Wolf in Sheep's Clothing". Med J Armed Forces India (2011) 0.78
Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology (1994) 4.77
Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J Gen Virol (1993) 2.50
Transcription of woodchuck hepatitis virus in the chronically infected liver. EMBO J (1985) 2.49
Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology (2001) 2.49
Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med (1985) 2.29
HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet (1994) 2.25
Transmission of hepatitis B virus by HBV-negative blood transfusion. Lancet (1995) 2.06
In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood (1998) 1.98
High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol (2001) 1.94
Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol (1992) 1.94
Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology (1990) 1.84
Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J Clin Invest (1996) 1.79
Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J Virol (1993) 1.71
Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol (2000) 1.59
Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma. Cell (1988) 1.58
Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology (2000) 1.56
Seroimmunologic classification of chronic hepatitis in 57 children. Hepatology (1983) 1.48
Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: relevance of pregenome encapsidation signal. Virology (1992) 1.47
Frequency and prognostic importance of thrombocytopenia in symptom-free HIV-infected individuals: a 5-year prospective study. AIDS (1991) 1.46
Clinical impact of occult HBV infections. J Clin Virol (2005) 1.46
Predictions of liver histology from laboratory tests and demographic data [corrected]. Lancet (1998) 1.39
Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology (1998) 1.37
Evidence that hepatitis B virus has a role in liver-cell carcinoma in alcoholic liver disease. N Engl J Med (1982) 1.37
Molecular basis of hepatitis B virus serotype variations within the four major subtypes. J Gen Virol (1992) 1.37
In vitro replication competence of a cloned hepatitis B virus variant with a nonsense mutation in the distal pre-C region. Virology (1991) 1.36
Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) (1995) 1.35
False-positive Western blot reactions to human immunodeficiency virus in blood donors. Lancet (1986) 1.31
Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks. Nature (1987) 1.25
Duck hepatitis B virus can tolerate insertion, deletion, and partial frameshift mutation in the distal pre-S region. J Virol (1989) 1.23
Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst (2000) 1.23
Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff. Lancet (1981) 1.21
Early detection of human immunodeficiency virus infection using third- and fourth-generation screening assays. Eur J Clin Microbiol Infect Dis (2001) 1.21
Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients. Lancet (1981) 1.18
Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second- and third-generation anti-HCV assays. Transfusion (1994) 1.16
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol Hepatol (2000) 1.16
Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology (1999) 1.15
Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. J Gen Virol (1999) 1.13
The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat (2013) 1.10
Laboratory infection with parvovirus B19. J Clin Pathol (1988) 1.07
Antibodies to hepatitis C virus in French blood donors. Lancet (1989) 1.07
Activation of Ki-ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure. Mol Carcinog (1991) 1.04
DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol (1995) 1.03
Rapid detection and further characterization of infection with hepatitis B virus variants containing a stop codon in the distal pre-C region. J Gen Virol (1990) 1.03
Current management strategies for hepatitis B in the elderly. Drugs Aging (2001) 1.03
Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol (1996) 1.03
Removal of cell-bound lipoproteins: a crucial step for the efficient infection of liver cells with hepatitis C virus in vitro. C R Acad Sci III (2001) 1.01
Effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks. J Med Virol (1992) 1.00
Two French genotypes of hepatitis C virus: homology of the predominant genotype with the prototype American strain. Gene (1991) 1.00
Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. J Infect Dis (2000) 0.99
Residues critical for duck hepatitis B virus neutralization are involved in host cell interaction. J Virol (1999) 0.99
Virus-neutralizing monoclonal antibody to a conserved epitope on the duck hepatitis B virus pre-S protein. J Virol (1990) 0.98
Transfusion-transmitted viral infections. Retrovirus and Viral Hepatitis Working Groups of the French Society of Blood Transfusion. N Engl J Med (1996) 0.98
Hepatitis B virus DNA in Dane particles: evidence for the presence of replicative intermediates. J Infect Dis (1985) 0.97
DNA amplification of HIV-1 in seropositive individuals and in seronegative at-risk individuals. AIDS (1990) 0.97
Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol (2007) 0.97
Use of a TT virus ORF1 recombinant protein to detect anti-TT virus antibodies in human sera. J Gen Virol (2000) 0.97
Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication. Antimicrob Agents Chemother (1998) 0.95
Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. DNA Cell Biol (1999) 0.95
Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors. Vox Sang (2000) 0.95
Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy. J Viral Hepat (2004) 0.95
2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob Agents Chemother (1996) 0.95
Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol (1998) 0.94
Human parvovirus and rheumatoid arthritis. Lancet (1985) 0.93
Early stages of rabbit haemorrhagic disease virus infection monitored by polymerase chain reaction. Zentralbl Veterinarmed B (1996) 0.93
Heterogeneity of hepatitis C virus genotypes in France. J Gen Virol (1994) 0.92
Early and frequent detection of HBxAg and/or anti-HBx in hepatitis B virus infection. Hepatology (1990) 0.92
Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon. J Med Virol (1997) 0.92
In vitro and in vivo replication capacity of the precore region defective hepatitis B virus variants. J Hepatol (1991) 0.92
HIV-2 in blood donors and in different risk groups in France. Lancet (1987) 0.91
Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon-alpha. J Viral Hepat (1998) 0.91
Complete nucleotide sequences of six hepatitis B viral genomes encoding the surface antigen subtypes ayw4, adw4q-, and adrq- and their phylogenetic classification. Arch Virol Suppl (1993) 0.90
Therapeutic activity of vidarabine in symptomatic chronic active hepatitis related to HBV. J Hepatol (1986) 0.90
Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology (1993) 0.90
No clinical signs 14 years after HIV-2 transmission via blood transfusion. Lancet (1988) 0.90
Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) (2009) 0.90
Hepatitis C virus genotypes in France: comparison of clinical features of patients infected with HCV type I and type II. J Hepatol (1994) 0.90
Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat (1998) 0.90
Role of silent hepatitis B virus in chronic hepatitis B surface antigen(-) liver disease. Antiviral Res (2001) 0.89
The hepatitis B virus and the peripheral blood mononuclear cells: a brief review. J Hepatol (1990) 0.89
Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol (1999) 0.89
Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. J Hepatol (2001) 0.89
Impact of screening donor blood for alanine aminotransferase and antibody to hepatitis B core antigen on the risk of hepatitis C virus transmission. Eur J Clin Microbiol Infect Dis (1993) 0.88
Long-term results of liver transplantation for Wilson's disease. Gastroenterol Clin Biol (2008) 0.88
Recent dramatic decrease in AIDS cases and HIV-related deaths contrasts with stable rate of new HIV-positive patients detected in Lyon, France, from 1988 to 1997. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 0.88
n-Butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes. J Virol (1996) 0.88
[Is GB virus C alias "hepatitis" G virus involved in human pathology?]. Transfus Clin Biol (2003) 0.87
Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy. J Viral Hepat (2000) 0.87
[Screening tests combined with p24 antigen and anti-HIV antibodies in early detection of HIV-1]. Transfus Clin Biol (2000) 0.87
Human parvovirus and aplastic crisis in chronic hemolytic anemias: a study of 24 observations. Am J Hematol (1986) 0.87
Monoclonal antibodies to HBsAg: a study of their specificities for eight different HBsAg subtypes. Dev Biol Stand (1983) 0.87
In vitro inhibition of hemopoietic cell line growth by hepatitis B virus. J Virol (1990) 0.87
Familial human parvovirus infections. Lancet (1985) 0.87
Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology (Oxford) (2005) 0.86
Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob Agents Chemother (2000) 0.86
Rapid screening for bacterial colonies harbouring tandem hepatitis B virus sequences by an oligonucleotide probe. J Virol Methods (1991) 0.86
Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis (1994) 0.86
Surveillance of equine influenza viruses through the RESPE network in France from November 2005 to October 2010. Equine Vet J (2013) 0.85